Close Menu

NEW YORK – Liquid biopsy firm Inivata said today that it is collaborating with the European Organization for Research and Treatment of Cancer, using its InVisionFirst-Lung test in a Pfizer-funded Phase II trial to test lung cancer patients under treatment with the ALK inhibitor lorlatinib (marketed as Lorbrena).

Investigators hope that this will help better define resistance mechanisms to the third-generation therapy, and potentially help unravel the impact of acquired resistance on response to sequential or combination therapies.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.